Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fined £84m for exploiting epilepsy drug price Pfizer hiked price by 2600%, says competition watchdog.
News BeyondSpring plans three-pronged attack on cancer The CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug and an innovative R&D strategy.
News Pfizer looks to confirm US licence for breast cancer pill Pfizer has filed late stage data with FDA.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Pfizer's hopes for cholesterol blockbuster dashed Sales of cancer drug Ibrance also fall short of expectations.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.